TY - JOUR
T1 - Socioeconomic status, race, and long-term outcomes after radical prostatectomy in an equal access health system
T2 - Results from the SEARCH database
AU - Everist, Mary M.
AU - Howard, Lauren E.
AU - Aronson, William J.
AU - Kane, Christopher J.
AU - Amling, Christopher L.
AU - Cooperberg, Matthew R.
AU - Terris, Martha K.
AU - Freedland, Stephen J.
N1 - Funding Information:
Funding: Funded by NIHHYB grant number(s) K24 CA160653 ; R01CA231219 .
Publisher Copyright:
© 2018
PY - 2019/4
Y1 - 2019/4
N2 - Introduction: We previously found racial differences in biochemical recurrence (BCR) after radical prostatectomy (RP) persisted after adjusting for socioeconomic status (SES) while SES did not predict BCR. The impact on long-term prostate cancer (PC) outcomes is unclear. We hypothesized higher SES would associate with better long-term outcomes regardless of race. Methods: Among 4,787 black and white men undergoing RP from 1988 to 2015 in the SEARCH Database, poverty (primary SES measure) was estimated by linking home ZIP-code to census data. Cox models were used to test the association between SES adjusting for demographic, clinicopathological features, and race with BCR, castration-resistant PC (CRPC), metastases, PC-specific mortality (PCSM), and all-cause mortality. Interactions between race and SES were tested. Results: Median follow-up was 98 months (Interquartile range: 54–150 months). There were no interactions between race and SES for BCR. Black men had 10%- to 11% increased BCR risk (P < 0.06) while SES was unrelated to BCR. There were interactions between SES and race for CRPC (P = 0.002), metastasis (P = 0.014), and PCSM (P = 0.004). Lower SES was associated with decreased CRPC (P = 0.012), metastases (P = 0.004), and PCSM (P = 0.049) in black, but not white men (all P ≥ 0.22). Higher SES was associated with decreased all-cause mortality in both races. Conclusions: In an equal-access setting, lower SES associated with decreased CRPC, metastases, and PCSM in black but not white men. If confirmed, these findings suggest a complex relationship between race, SES, and PC with further research needed to understand why low SES in black men decreased the risk for poor PC outcomes after RP.
AB - Introduction: We previously found racial differences in biochemical recurrence (BCR) after radical prostatectomy (RP) persisted after adjusting for socioeconomic status (SES) while SES did not predict BCR. The impact on long-term prostate cancer (PC) outcomes is unclear. We hypothesized higher SES would associate with better long-term outcomes regardless of race. Methods: Among 4,787 black and white men undergoing RP from 1988 to 2015 in the SEARCH Database, poverty (primary SES measure) was estimated by linking home ZIP-code to census data. Cox models were used to test the association between SES adjusting for demographic, clinicopathological features, and race with BCR, castration-resistant PC (CRPC), metastases, PC-specific mortality (PCSM), and all-cause mortality. Interactions between race and SES were tested. Results: Median follow-up was 98 months (Interquartile range: 54–150 months). There were no interactions between race and SES for BCR. Black men had 10%- to 11% increased BCR risk (P < 0.06) while SES was unrelated to BCR. There were interactions between SES and race for CRPC (P = 0.002), metastasis (P = 0.014), and PCSM (P = 0.004). Lower SES was associated with decreased CRPC (P = 0.012), metastases (P = 0.004), and PCSM (P = 0.049) in black, but not white men (all P ≥ 0.22). Higher SES was associated with decreased all-cause mortality in both races. Conclusions: In an equal-access setting, lower SES associated with decreased CRPC, metastases, and PCSM in black but not white men. If confirmed, these findings suggest a complex relationship between race, SES, and PC with further research needed to understand why low SES in black men decreased the risk for poor PC outcomes after RP.
KW - Castration-resistant
KW - Equal-access
KW - Metastasis
KW - Prostate cancer
KW - Race
KW - Socioeconomic status
UR - http://www.scopus.com/inward/record.url?scp=85059174383&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059174383&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2018.12.004
DO - 10.1016/j.urolonc.2018.12.004
M3 - Article
C2 - 30598238
AN - SCOPUS:85059174383
SN - 1078-1439
VL - 37
SP - 289.e11-289.e17
JO - Urologic Oncology
JF - Urologic Oncology
IS - 4
ER -